AngioDynamics reports Q1 adjusted EPS (10c), consensus (12c)

Reports Q1 revenue $75.7M, consensus $72.69M. Ended FY26 Q1 with $38.8M in cash and cash equivalents, ahead of expectations, continues to expect to be cash flow positive for the full year FY26. “We had an outstanding first quarter as we continued to build off of the strong momentum created in FY25,” commented CEO Jim Clemmer. “Our strategy to bring unique platform technologies to large, fast growing global markets has paid off as we reported our fourth quarter in a row of MedTech growth of over 20%. This continued performance, combined with our disciplined focus on operational excellence, is driving sustained profitable growth. Our exceptional team is executing our vision to deliver transformative technologies that expand treatment options and help patients live healthier, happier lives. With our superior technologies supported by our clinical investments and the strength of our balance sheet, we remain well-positioned to drive consistent, profitable growth, and deliver sustained value creation during the balance of 2026 and beyond.”